financetom
DARE
financetom
/
Healthcare
/
DARE
All stocks News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Commodities
Daré Bioscience, Inc.DARE
USD
- At close
USD
- Until the end
The complete list of US stocks
1D
5D
1M
1Y
5Y
MAX
Overview >
% Change
Description >

Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in the identifying, developing, and marketing products for women's health in the United States.

It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health.

The company's product includes XACIATO, a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in female patients 12 years of age and older.

Its products in advanced clinical development include Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder; and DARE-HRT1, a combination of bio-identical estradiol and progesterone intravaginal ring for the treatment of vasomotor symptoms in hormone therapy.

The company's Phase I-ready products are DARE-VVA1, a proprietary formulation of tamoxifen for intravaginal to treat vulvar vaginal atrophy in women with hormone-receptor positive breast cancer; DARE-PDM1, a proprietary hydrogel formulation of diclofenac, a nonsteroidal anti-inflammatory drug, for vaginal administration as a treatment for dysmenorrhea; DARE-204 and DARE-214, an injectable formulations of etonogestrel to provide contraception over 6-month and 12-month periods; and DARE-FRT1, an intravaginal ring containing bio-identical progesterone for broader luteal phase support as part of an in vitro fertilization treatment plan, as well as DARE-PTB1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth.

Its products in pre-clinical stage include DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-GML, an intravaginally-delivered potential multi-target antimicrobial agent formulated with glycerol monolaurate; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal healt

Latest News >
Accenture Insider Sold Shares Worth $1,200,855, According to a Recent SEC Filing
Accenture Insider Sold Shares Worth $1,200,855, According to a Recent SEC Filing
Apr 16, 2024
04:22 PM EDT, 04/16/2024 (MT Newswires) -- Julie Spellman Sweet, Director, Chair and CEO, on April 12, 2024, sold 3,801 shares in Accenture ( ACN ) for $1,200,855. Following the Form 4 filing with the SEC, Sweet has control over a total of 15,178 shares of the company, with 15,178 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1467373/000146737324000131/xslF345X03/wk-form4_1713298263.xml ...
Dutch Senate approves law to permanently close Groningen gas field
Dutch Senate approves law to permanently close Groningen gas field
Apr 16, 2024
AMSTERDAM, April 16 (Reuters) - The Dutch Senate on Tuesday approved a law to permanently close the Groningen gas field in the north of the Netherlands, following the government's promise that production will never be resumed to limit seismic risks in the region. Normal gas production at Groningen in the north of the Netherlands ended last October after years of...
Hancock Whitney Q1 Earnings, Revenue Decline
Hancock Whitney Q1 Earnings, Revenue Decline
Apr 16, 2024
04:22 PM EDT, 04/16/2024 (MT Newswires) -- Hancock Whitney ( HWC ) reported Q1 earnings Tuesday of $1.24 per diluted share, down from $1.45 a year earlier. Analysts polled by Capital IQ expected $1.17. Revenue in the quarter ended March 31, expressed as the sum of net interest income and noninterest income, was $354 million, down from $365.3 million a...
Accenture Insider Sold Shares Worth $474,213, According to a Recent SEC Filing
Accenture Insider Sold Shares Worth $474,213, According to a Recent SEC Filing
Apr 16, 2024
04:23 PM EDT, 04/16/2024 (MT Newswires) -- Manish Sharma, CEO, North America, on April 12, 2024, sold 1,501 shares in Accenture ( ACN ) for $474,213. Following the Form 4 filing with the SEC, Sharma has control over a total of 3,122 shares of the company, with 3,122 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1467373/000146737324000130/xslF345X03/wk-form4_1713298245.xml ...
Copyright 2023-2025 - www.financetom.com All Rights Reserved